BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 17223160)

  • 1. Design, synthesis and melatoninergic potency of new N-acyl 8,9-dihydro-4-methoxy-7H-2-benzo[de]quinolinalkanamines.
    Tsotinis A; Eleutheriades A; Hough KA; Davidson K; Sugden D
    Bioorg Chem; 2007 Apr; 35(2):189-204. PubMed ID: 17223160
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis and melatoninergic activity of new unsubstituted and beta,beta'-difunctionalised 2,3-dihydro-1H-pyrrolo[3,2,1-ij]quinolin-6-alkanamides.
    Tsotinis A; Panoussopoulou M; Eleutheriades A; Davidson K; Sugden D
    Eur J Med Chem; 2007 Jul; 42(7):1004-13. PubMed ID: 17346859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mapping the melatonin receptor. 7. Subtype selective ligands based on beta-substituted N-acyl-5-methoxytryptamines and beta-substituted N-acyl-5-methoxy-1-methyltryptamines.
    Tsotinis A; Vlachou M; Papahatjis DP; Calogeropoulou T; Nikas SP; Garratt PJ; Piccio V; Vonhoff S; Davidson K; Teh MT; Sugden D
    J Med Chem; 2006 Jun; 49(12):3509-19. PubMed ID: 16759094
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tricyclic alkylamides as melatonin receptor ligands with antagonist or inverse agonist activity.
    Lucini V; Pannacci M; Scaglione F; Fraschini F; Rivara S; Mor M; Bordi F; Plazzi PV; Spadoni G; Bedini A; Piersanti G; Diamantini G; Tarzia G
    J Med Chem; 2004 Aug; 47(17):4202-12. PubMed ID: 15293992
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mapping the melatonin receptor. 5. Melatonin agonists and antagonists derived from tetrahydrocyclopent[b]indoles, tetrahydrocarbazoles and hexahydrocyclohept[b]indoles.
    Davies DJ; Garratt PJ; Tocher DA; Vonhoff S; Davies J; Teh MT; Sugden D
    J Med Chem; 1998 Feb; 41(4):451-67. PubMed ID: 9484496
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design and synthesis of N-(3,3-diphenylpropenyl)alkanamides as a novel class of high-affinity MT2-selective melatonin receptor ligands.
    Bedini A; Spadoni G; Gatti G; Lucarini S; Tarzia G; Rivara S; Lorenzi S; Lodola A; Mor M; Lucini V; Pannacci M; Scaglione F
    J Med Chem; 2006 Dec; 49(25):7393-403. PubMed ID: 17149869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mapping the melatonin receptor. 6. Melatonin agonists and antagonists derived from 6H-isoindolo[2,1-a]indoles, 5,6-dihydroindolo[2,1-a]isoquinolines, and 6,7-dihydro-5H-benzo[c]azepino[2,1-a]indoles.
    Faust R; Garratt PJ; Jones R; Yeh LK; Tsotinis A; Panoussopoulou M; Calogeropoulou T; Teh MT; Sugden D
    J Med Chem; 2000 Mar; 43(6):1050-61. PubMed ID: 10737738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and biological activity of new melatonin dimeric derivatives.
    Di Giacomo B; Bedini A; Spadoni G; Tarzia G; Fraschini F; Pannacci M; Lucini V
    Bioorg Med Chem; 2007 Jul; 15(13):4643-50. PubMed ID: 17481904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the structure-activity relationships of melatonin receptor agonists and antagonists: lengthening the N-acyl side-chain has differing effects on potency on Xenopus melanophores.
    Teh MT; Sugden D
    Naunyn Schmiedebergs Arch Pharmacol; 1998 Nov; 358(5):522-8. PubMed ID: 9840420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 7-Substituted-melatonin and 7-substituted-1-methylmelatonin analogues: effect of substituents on potency and binding affinity.
    Faust R; Garratt PJ; Trujillo Pérez MA; Piccio VJ; Madsen C; Stenstrøm A; Frølund B; Davidson K; Teh MT; Sugden D
    Bioorg Med Chem; 2007 Jul; 15(13):4543-51. PubMed ID: 17459711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of structure-activity relationships for MT2 selective antagonists by melatonin MT1 and MT2 receptor models.
    Rivara S; Lorenzi S; Mor M; Plazzi PV; Spadoni G; Bedini A; Tarzia G
    J Med Chem; 2005 Jun; 48(12):4049-60. PubMed ID: 15943478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis of 3-phenylnaphthalenic derivatives as new selective MT(2) melatoninergic ligands.
    Poissonnier-Durieux S; Ettaoussi M; Pérès B; Boutin JA; Audinot V; Bennejean C; Delagrange P; Caignard DH; Renard P; Berthelot P; Lesieur D; Yous S
    Bioorg Med Chem; 2008 Sep; 16(18):8339-48. PubMed ID: 18778943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. N-(substituted-anilinoethyl)amides: design, synthesis, and pharmacological characterization of a new class of melatonin receptor ligands.
    Rivara S; Lodola A; Mor M; Bedini A; Spadoni G; Lucini V; Pannacci M; Fraschini F; Scaglione F; Sanchez RO; Gobbi G; Tarzia G
    J Med Chem; 2007 Dec; 50(26):6618-26. PubMed ID: 18052314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and synthesis of new N1 and C3-substituted 4-fluoroindolic melatoninergics.
    Tsotinis A; Eleutheriades A; Davidson K; Sugden D
    Curr Drug Discov Technol; 2007 Oct; 4(3):198-207. PubMed ID: 17986002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis, enantiomeric resolution, and structure-activity relationship study of a series of 10,11-dihydro-5H-dibenzo[a,d]cycloheptene MT2 receptor antagonists.
    Spadoni G; Bedini A; Diamantini G; Tarzia G; Rivara S; Lorenzi S; Lodola A; Mor M; Lucini V; Pannacci M; Caronno A; Fraschini F
    ChemMedChem; 2007 Dec; 2(12):1741-9. PubMed ID: 17907131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bicyclic melatonin receptor agonists containing a ring-junction nitrogen: Synthesis, biological evaluation, and molecular modeling of the putative bioactive conformation.
    Elsner J; Boeckler F; Davidson K; Sugden D; Gmeiner P
    Bioorg Med Chem; 2006 Mar; 14(6):1949-58. PubMed ID: 16290939
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and pharmacological evaluation of 1,2,3,4-tetrahydropyrazino[1,2-a]indole and 2-[(phenylmethylamino)methyl]-1H-indole analogues as novel melatoninergic ligands.
    Markl C; Attia MI; Julius J; Sethi S; Witt-Enderby PA; Zlotos DP
    Bioorg Med Chem; 2009 Jul; 17(13):4583-94. PubMed ID: 19473848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and synthesis of 3-phenyltetrahydronaphthalenic derivatives as new selective MT2 melatoninergic ligands. Part II.
    Durieux S; Chanu A; Bochu C; Audinot V; Coumailleau S; Boutin JA; Delagrange P; Caignard DH; Bennejean C; Renard P; Lesieur D; Berthelot P; Yous S
    Bioorg Med Chem; 2009 Apr; 17(8):2963-74. PubMed ID: 19329323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and synthesis of 1-(2-alkanamidoethyl)-6-methoxy-7-azaindole derivatives as potent melatonin agonists.
    Jeanty M; Suzenet F; Delagrange P; Nosjean O; Boutin JA; Caignard DH; Guillaumet G
    Bioorg Med Chem Lett; 2011 Apr; 21(8):2316-9. PubMed ID: 21420861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The putative melatonin receptor antagonist GR128107 is a partial agonist on Xenopus laevis melanophores.
    Teh MT; Sugden D
    Br J Pharmacol; 1999 Mar; 126(5):1237-45. PubMed ID: 10205014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.